Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) had its price objective decreased by Chardan Capital from $10.00 to $5.50 in a research report report published on Wednesday morning. Chardan Capital currently has a buy rating on the stock.

Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 2.36 on Wednesday. The firm has a 50-day moving average of $3.88 and a 200-day moving average of $4.58. Aralez Pharmaceuticals has a 1-year low of $2.05 and a 1-year high of $6.80. The stock’s market capitalization is $154.58 million.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its earnings results on Monday, March 13th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.11. Aralez Pharmaceuticals had a negative return on equity of 65.67% and a negative net margin of 211.76%. The company had revenue of $20 million for the quarter, compared to analyst estimates of $21.86 million. During the same quarter in the previous year, the company posted ($0.40) earnings per share. The company’s quarterly revenue was up 233.3% compared to the same quarter last year. Equities research analysts anticipate that Aralez Pharmaceuticals will post ($1.07) EPS for the current year.

Your IP Address:

In related news, Director Arthur S. Kirsch bought 45,000 shares of the stock in a transaction on Wednesday, March 15th. The shares were bought at an average cost of $2.27 per share, for a total transaction of $102,150.00. Following the completion of the transaction, the director now owns 149,109 shares of the company’s stock, valued at approximately $338,477.43. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Adrian Adams bought 500,000 shares of the stock in a transaction on Wednesday, March 15th. The shares were bought at an average price of $2.46 per share, for a total transaction of $1,230,000.00. Following the completion of the transaction, the chief executive officer now directly owns 3,569,230 shares of the company’s stock, valued at approximately $8,780,305.80. The disclosure for this purchase can be found here. Insiders have acquired 549,750 shares of company stock worth $1,342,173 over the last 90 days. 6.77% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Broadfin Capital LLC boosted its position in shares of Aralez Pharmaceuticals by 8.7% in the fourth quarter. Broadfin Capital LLC now owns 4,791,590 shares of the company’s stock worth $21,131,000 after buying an additional 384,600 shares during the last quarter. Armistice Capital LLC boosted its position in shares of Aralez Pharmaceuticals by 35.0% in the fourth quarter. Armistice Capital LLC now owns 2,836,000 shares of the company’s stock worth $12,507,000 after buying an additional 736,000 shares during the last quarter. JW Asset Management LLC boosted its position in shares of Aralez Pharmaceuticals by 2.5% in the fourth quarter. JW Asset Management LLC now owns 2,680,140 shares of the company’s stock worth $11,820,000 after buying an additional 65,000 shares during the last quarter. Tiger Legatus Capital Management LLC boosted its position in shares of Aralez Pharmaceuticals by 1.3% in the fourth quarter. Tiger Legatus Capital Management LLC now owns 1,985,000 shares of the company’s stock worth $8,754,000 after buying an additional 25,000 shares during the last quarter. Finally, Drill Craig A boosted its position in shares of Aralez Pharmaceuticals by 64.0% in the third quarter. Drill Craig A now owns 958,945 shares of the company’s stock worth $4,651,000 after buying an additional 374,345 shares during the last quarter. Institutional investors own 44.01% of the company’s stock.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

5 Day Chart for NASDAQ:ARLZ

Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.